COSCIENS Biopharma Inc.
CSCI.TO
TSX
| 06/30/2024 | 03/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 13.61% | 1,600.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 13.61% | 1,600.00% | |||
| Cost of Revenue | 31.66% | 1,996.36% | |||
| Gross Profit | -9.40% | 1,269.70% | |||
| SG&A Expenses | 226.05% | -193.10% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3,146.00% | -103.07% | |||
| Operating Income | -266.37% | 135.29% | |||
| Income Before Tax | -4.58% | 67.83% | |||
| Income Tax Expenses | -15.05% | -- | |||
| Earnings from Continuing Operations | -1.50% | 75.14% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1.50% | 75.14% | |||
| EBIT | -266.37% | 135.29% | |||
| EBITDA | -229.13% | 140.93% | |||
| EPS Basic | 15.57% | 83.66% | |||
| Normalized Basic EPS | -169.53% | 124.11% | |||
| EPS Diluted | 15.57% | 83.66% | |||
| Normalized Diluted EPS | -169.53% | 124.11% | |||
| Average Basic Shares Outstanding | 20.22% | 52.13% | |||
| Average Diluted Shares Outstanding | 20.22% | 52.13% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||